Endo’s Generics Face Competitive Pressures
Company Sees Predicted Decline In Overall & Generics Revenues
After seeing increased demand because of COVID-19 in the first quarter of 2020, Endo’s generics segment has seen a predicted decrease in revenues in the second quarter. Furthermore, the company has also predicted an unfavorable impact due to competitive pressures for 2020 as a whole.
You may also be interested in...
Endo will focus on restructuring initiatives and new launches in 2021 to stabilize its generics business, after the company reported a 20% drop in generics sales for the fourth quarter of 2020, with full-year sales down by more than a tenth.
As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.
Dr Reddy’s Laboratories has leapfrogged Endo by launching a generic version of of Bayer/Alcon’s Ciprodex (ciprofloxacin/dexamethasone) 0.3%/0.1% otic suspension, as the US firm was stung with a major rejection by the US FDA.